|
Last week, President Trump signed an executive order aimed at accelerating access to medical treatments for serious mental illness, including research into ibogaine, a substance known for its psychoactive effects.
This week, the Administration and the US Department of Justice announced a reclassification of state-licensed medical marijuana, moving it from a Schedule I to a Schedule III substance.
What does this mean? Changes like these can influence how substances are perceived—often lowering perceived risk while increasing acceptance and potential availability. For communities, this raises important considerations around access, messaging, youth prevention, and ensuring that education and safeguards keep pace with policy shifts.
⭐Bonus Related Articles🗞️
How ibogaine become the darling of the psychedelic right RollingStone
US Cannabis Map Great Lakes PTTC via Facebook
Our 'cannabis' vocabulary is eroding public health safeguards American Journal of Public Health via CADCA
What THC drinks can - and can't - do for sleep, stress, and pain Food & Wine via Yahoo
Worth repeating! There are no positives for young adult cannabis users Psychology Today
|